Teriparatide is a recombinant form of human parathyroid hormone that stimulates new bone formation by preferentially activating osteoblasts. Its primary healthspan relevance is the significant reduction of fracture risk in individuals with severe osteoporosis, a condition that dramatically increases morbidity, mortality, and loss of independence with age.
Verdict
A powerful, targeted tool for severe osteoporosis, not a general longevity drug.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
High
EVIDENCE GRADE
A
MONTHLY COST
$1000 - $4000
Protocol
- 20 mcg administered daily via subcutaneous injection, typically for a lifetime maximum of 2 years.
Flags
- Black box warning for a potential increased risk of osteosarcoma.
- Lifetime use is typically limited to a cumulative total of 24 months.
- Requires a prescription and ongoing medical supervision.
- May cause hypercalcemia, dizziness, nausea, and leg cramps.
- Contraindicated in patients with Paget's disease or prior skeletal radiation therapy.